Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sign Of Normalcy? US FDA Schedules Meeting But Pauses Non-COVID Guidance Development

May 19 2020

• By Derrick Gingery

Stop Wait Go Glossy Button, Vector illustration

Related Content

US FDA Tech Modernization Plan’s Costs Uncertain

Feb 23 2020

Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began

Apr 30 2020

Virtual Advisory Committees Are Coming: US FDA Panels Will Be Smaller, More Focused

Apr 15 2020

US FDA Greenlighting Dozens Of New Trials For Coronavirus Therapeutics

Apr 21 2020

US FDA May Start To Miss User Fee Deadlines

Apr 17 2020

Podcast: CDER’s Woodcock On COVID-19 – Missed User Fees Unlikely, But Some Work Will Be ‘Set Aside’

Apr 01 2020

No End In Sight: FDA Postpones Another In-Person Meeting Due To COVID-19

Apr 30 2020

Coronavirus Slams US Consumer Health Industry Event Schedules, FDA Meetings, Inspections

Mar 10 2020

US OTC Monograph Reform's Early Results Could Be Label Orders From FDA, Wait And See For Industry

Apr 16 2020

Additional Topics

International United States FDA Advisory Committees Coronavirus COVID-19 Commercial Clinical Trials Compliance Drug Approval Standards Dietary Supplements Cosmetics Drug Review Ingredients Manufacturing OTC Drugs Policy Regulation Consumer

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window